Menu
Back to Journals » Drug Design, Development and Therapy » Volume 16
Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
Authors Ranzenigo M, Gianotti N , Galli L , Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M , Nozza S, Bossolasco S, Spagnuolo V , Mancusi D , Termini R , Carini E, Lazzarin A, Castagna A
Received 19 October 2022
Accepted for publication 19 October 2022
Published 27 October 2022 Volume 2022:16 Pages 3737—3738
Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982.
Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNRTIs in 32 (30.2%) and on InSTIs in 74 (69.8%)”.
Page 1977, Results, last paragraph, line one, the text “a longer exposure” should read “a shorter exposure”.
Page 1980, first paragraph, lines one and two, the text “(a longer history of infection and a previous diagnosis of AIDS)” should read “(a previous diagnosis of AIDS)”.
Page 1980, Table 2, last row, the category INSTI-based vs NNRTI-based for the BL ART (type of non-PI regimen) characteristic is incorrect and should read “NNRTI-based vs INSTI-based”. The correct Table 2is shown below.
 |
Table 2 Factors Associated with the Switch to D/C/F/TAF |
The authors apologise for the errors and advise they do not affect the results of the paper.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.